Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).

What Was Tested

Researchers studied Doxorubicin in the context of endometriosis in this phase 2 clinical trial publication.

Advanced or recurrent endometrial cancer (EC) no longer amenable to surgery or radiotherapy is a life-threatening disease with limited therapeutic options left.

Eighty percent of ECs express receptors for luteinizing hormone-releasing hormone (LHRH), which can be targeted by AEZS-108 (zoptarelin doxorubicin acetate).

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, women only.

Patients had FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) III or IV or recurrent EC, LHRH receptor-positive tumor status, and at least had 1 measurable lesion (Response Evaluation Criteria in Solid Tumors).

Patients received AEZS-108 as a 2-hour infusion on day 1 of a 21-day cycle.

How the Study Was Run

Prior anthracycline therapy was not allowed.

The treatment was continued for a maximum of 6 to 8 cycles.

The primary end point was the response rate determined by the Response Evaluation Criteria in Solid Tumors.

What Was Measured

PubMed files the paper under topics including Doxorubicin, Endometrial Neoplasms, Gonadotropin-Releasing Hormone, Neoplasm Recurrence, Local and Receptors, LHRH.

What This Means in Plain Language

This is a phase 2 clinical trial of Doxorubicin in people with endometriosis.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society), a journal based in United States.

More context: Endometriosis research.